The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating lenacapavir, a long-lasting HIV prevention and treatment drug.

Wesley Sundquist, a biochemist at the University of Utah, was recently featured in Time's annual "100 Most Influential People ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.

The most recent addition to preventing the spread of HIV is a bi-annual injection called lenacapavir that can prevent HIV contraction for women. “An injection twice a year could revolutionise HIV ...

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.